Opportunities and Challenges
HCV cascade
HCV curative treatment
HCV screening
Hepatitis C
MOUD provider health services
Journal
AJPM focus
ISSN: 2773-0654
Titre abrégé: AJPM Focus
Pays: England
ID NLM: 9918487585606676
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
medline:
4
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
The purpose of this study was to characterize hepatitis C virus screening and treatment access experiences among people in treatment for opioid use disorder in Arizona during COVID-19. Arizonans receiving treatment for opioid use disorder from methadone clinics and buprenorphine providers during COVID-19 were interviewed about hepatitis C virus testing, curative treatment, and knowledge about screening recommendations. Interviews were conducted with 121 people from August 4, 2021 to October 10, 2021. Qualitative data were coded using the categories of hepatitis C virus testing, knowledge of screening recommendations, diagnosis, and experiences seeking curative treatment. Data were also quantitated for bivariate testing with outcome variables of last hepatitis C virus test, diagnosis, and curative treatment process. Findings were arrayed along an adapted hepatitis C virus cascade framework to inform program and policy improvements. Just over half of the sample reported ever having tested for hepatitis C virus (51.2%, Structural barriers continue to prevent curative hepatitis C virus treatment access. Given that methadone and buprenorphine treatment providers serve patients who are largely undiagnosed or treated for hepatitis C virus, opportunities exist for them to screen their patients regularly and provide support for and/or navigation to hepatitis C virus curative treatment.
Identifiants
pubmed: 37789937
doi: 10.1016/j.focus.2022.100047
pii: S2773-0654(22)00045-1
pmc: PMC10546500
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100047Informations de copyright
© 2022 The Author(s).
Références
Drug Alcohol Depend. 2019 May 1;198:80-86
pubmed: 30884432
Addiction. 2014 Mar;109(3):452-9
pubmed: 24678545
PLoS One. 2022 Oct 25;17(10):e0274094
pubmed: 36282806
Ann Intern Med. 2015 Aug 4;163(3):226-8
pubmed: 26121095
Int J Drug Policy. 2021 Jul;93:103112
pubmed: 33461838
Drug Alcohol Depend. 2017 Feb 01;171:31-38
pubmed: 28012429
Liver Int. 2018 Feb;38(2):258-265
pubmed: 28719013
Clin Infect Dis. 2012 May;54(9):1259-71
pubmed: 22412061
Ann Intern Med. 2015 Aug 4;163(3):215-23
pubmed: 26120969
J Public Health Manag Pract. 2020 Nov/Dec;26(6):562-569
pubmed: 31094863
MMWR Recomm Rep. 2020 Apr 10;69(2):1-17
pubmed: 32271723
Gastroenterol Hepatol (N Y). 2018 Dec;14(12):720-722
pubmed: 30804720
Int Rev Psychiatry. 2007 Apr;19(2):113-22
pubmed: 17464789
Am J Public Health. 2022 Apr;112(S2):S117-S122
pubmed: 35349312
J Public Health Manag Pract. 2019 May/Jun;25(3):245-252
pubmed: 29927900
J Infect Dis. 2020 Sep 2;222(Suppl 5):S365-S375
pubmed: 32877566
Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35
pubmed: 23490450
Addiction. 2008 Jun;103(6):905-18
pubmed: 18422827
Addiction. 2020 Aug;115(8):1509-1521
pubmed: 31984606
Am J Public Health. 2016 Feb;106(2):353-8
pubmed: 26562129
J Subst Abuse Treat. 2019 May;100:45-51
pubmed: 30898327
Hepatology. 2019 Mar;69(3):1020-1031
pubmed: 30398671
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):437-441
pubmed: 31603512